1-(2,4-dichloro-phenyl)-5-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid | 1040394-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2,4-dichloro-phenyl)-5-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid
• 英文别名: 2-(2,4-Dichlorophenyl)-3-methyl-4-phenyl-3,4-dihydropyrazole-5-carboxylic acid
• CAS: 1040394-81-7
• 化学式: C₁₇H₁₄Cl₂N₂O₂
• 分子量: 349.216
• InChiKey: JWVVGZFMZPFXTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1947087A1

  公开（公告）日：2008-07-23

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及替代吡唑啉化合物，其制备方法，包含这些化合物的药物，以及它们用于制备用于治疗人类和动物，特别是在血脂异常方面的药物的用途。
• SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY
  申请人：Yenes-Minguez Susana

  公开号：US20100099712A1

  公开（公告）日：2010-04-22

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及取代吡唑烷化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物，特别是在脂质代谢异常症方面的药物的用途。
• [EN] SUBSTITUTED PYRAZOLINE COMPOUNDS WITH ACAT INHIBITION ACTIVITY<br/>[FR] COMPOSÉS DE PYRAZOLINE SUBSTITUÉE POSSÉDANT UNE ACTIVITÉ D'INHIBITION DE L'ACAT
  申请人：ESTEVE LABOR DR

  公开号：WO2008087029A1

  公开（公告）日：2008-07-24

  [EN] The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.
  [FR] La présente invention concerne des composés de pyrazoline substituée, des procédés de préparation, des médicaments comprenant ces composés ainsi que leur utilisation pour la préparation d'un médicament destiné au traitement d'êtres humains et d'animaux, spécialement dans le cas d'une dyslipidémie.